病毒感染相关天疱疮

doi:10.13591/j.cnki.kqyx.2023.09.016

摘要/Abstract

摘要：

天疱疮是一组可累及全身皮肤黏膜的自身免疫性大疱性疾病,其病因主要包括遗传易感性及环境因素两大类。病毒感染作为重要的环境因素被认为与天疱疮的发生关系密切。单纯疱疹病毒、肝炎病毒及其他类型的病毒感染均可能是天疱疮的触发因素;其潜在机制涉及分子拟态、抗原抗体免疫复合物的持续形成及异常的T细胞亚群分化及功能等多方面;对于合并病毒感染的天疱疮患者,常规糖皮质激素或免疫抑制剂治疗联合抗病毒治疗往往能取得更好的疗效。该文从病毒感染与天疱疮的关系、潜在致病机制以及临床治疗方案选择方面对病毒感染相关天疱疮作一综述。

关键词: 天疱疮, 寻常型天疱疮, 病毒感染, 自身免疫, 抗病毒治疗

Abstract:

Pemphigus is a group of autoimmune bullous diseases that can affect skin and mucosa. The etiology mainly includes genetic susceptibility and environmental factors. As one of the critical environmental factors, virus infection is considered to be closely related to the occurrence of pemphigus. Herpes simplex virus, hepatitis virus, and other viral infections may all trigger pemphigus. The potential mechanism involves molecular mimicry, continuous formation of antigen-antibody immune complexes, and abnormal differentiation and function of T cell subsets. Pemphigus patients with viral infection may benefit from combining conventional glucocorticoid or immunosuppressive therapy and antiviral therapy. This article reviews the relationship between viral infection and pemphigus, the potential pathogenic mechanism, and the selection of clinical treatment options for viral infection-related pemphigus.

Key words: pemphigus, pemphigus vulgaris, viral infection, autoimmune, antiviral therapy

中图分类号:

R781.53

周航帆, 江潞. 病毒感染相关天疱疮[J]. 口腔医学, 2023, 43(9): 854-860.

ZHOU Hangfan, JIANG Lu. Viral infection-related pemphigus[J]. Stomatology, 2023, 43(9): 854-860.

图/表 2

参考文献 82

[1]	Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid[J]. J Allergy ClinImmunol, 2020, 145(4):1031-1047. doi: 10.1016/j.jaci.2020.02.013
[2]	Pollmann R, Schmidt T, Eming R, et al. Pemphigus:A comprehensive review on pathogenesis, clinical presentation and novel therapeutic approaches[J]. Clinic Rev AllergImmunol, 2018, 54(1):1-25.
[3]	Kridin K. Pemphigus group:Overview, epidemiology, mortality, and comorbidities[J]. Immunol Res, 2018, 66(2):255-270. doi: 10.1007/s12026-018-8986-7
[4]	Di Lernia V, Casanova DM, Goldust M, et al. Pemphigus vulgaris and bullous pemphigoid:Update on diagnosis and treatment[J]. Dermatol Pract Concept, 2020, 10(3):e2020050.
[5]	Siddig O, Mustafa MB, Kordofani Y, et al. The epidemiology of autoimmune bullous diseases in Sudan between 2000 and 2016[J]. PLoS One, 2021, 16(7):e0254634. doi: 10.1371/journal.pone.0254634
[6]	Didona D, Maglie R, Eming R, et al. Pemphigus:Current and future therapeutic strategies[J]. Front Immunol, 2019, 10:1418. doi: 10.3389/fimmu.2019.01418 pmid: 31293582
[7]	Kridin K, Zelber-Sagi S, Bergman R. Pemphigus vulgaris and Pemphigus foliaceus:Differences in epidemiology and mortality[J]. Acta Derm Venereol, 2017, 97(9):1095-1099. doi: 10.2340/00015555-2706
[8]	Porro AM, Seque CA, Ferreira MCC, et al. Pemphigus vulgaris[J]. An Bras Dermatol, 2019, 94(3):264-278. doi: S0365-05962019000300264 pmid: 31365654
[9]	Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus[J]. Nat Rev Dis Primers, 2017, 3:17026. doi: 10.1038/nrdp.2017.26 pmid: 28492232
[10]	Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: A systematic review of 170 patients[J]. Int Immunopharmacol, 2021, 92:107299. doi: 10.1016/j.intimp.2020.107299
[11]	Kurata M, Mizukawa Y, Aoyama Y, et al. Herpes simplex virus reactivation as a trigger of mucous lesions in pemphigus vulgaris[J]. Br J Dermatol, 2014, 171(3):554-560. doi: 10.1111/bjd.12961 pmid: 24660994
[12]	Kridin K, Zelber-Sagi S, Comaneshter D, et al. Is there an association between pemphigus and hepatitis viruses? A population-based large-scale study[J]. Immunol Res, 2017, 65(5):1083-1088. doi: 10.1007/s12026-017-8950-y pmid: 28905194
[13]	Horiguchi Y, Fujii S, Takase S, et al. Case of pemphigus vulgaris in oral mucosa showing an extension to the body surface with recurrent varicella[J]. Int J Dermatol, 2005, 44(11):951-954. pmid: 16336532
[14]	Murata T, Morita K. Unsuspected varicella-zoster infection complicating mucosal-dominant pemphigus vulgaris[J]. Int J Dermatol, 2013, 52(11):1453-1454. doi: 10.1111/j.1365-4632.2011.05393.x pmid: 23879518
[15]	Oliveira-Batista DP, Janini MER, Fernandes NC, et al. Laboratory diagnosis of herpesvirus infections in patients with Pemphigus vulgaris lesions[J]. Intervirology, 2013, 56(4):231-236. doi: 10.1159/000349889 pmid: 23735576
[16]	Meibodi NT, Nahidi Y, Mahmoudi M, et al. Evaluation of coexistence of the Human Herpesvirus type 8 (HHV-8) infection and pemphigus[J]. Int J Dermatol, 2010, 49(7):780-783. doi: 10.1111/j.1365-4632.2009.04398.x pmid: 20618497
[17]	Markitziu A, Pisanty S. Pemphigus vulgaris after infection by Epstein-Barr virus[J]. Int J Dermatol, 1993, 32(12):917-918. pmid: 8125704
[18]	Singh A, Bharadwaj SJ, Chirayath AG, et al. Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature[J]. J Cosmet Dermatol, 2022, 21(6):2311-2314. doi: 10.1111/jocd.v21.6
[19]	Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirusentry[J]. Nat Rev Microbiol, 2021, 19(2):110-121. doi: 10.1038/s41579-020-00448-w pmid: 33087881
[20]	Zhu SY, Viejo-Borbolla A. Pathogenesis and virulence of Herpes simplexvirus[J]. Virulence, 2021, 12(1):2670-2702. doi: 10.1080/21505594.2021.1982373
[21]	Krain LS. Pemphigus. Epidemiologic and survival characteristics of 59 patients, 1955-1973[J]. Arch Dermatol, 1974, 110(6):862-865. doi: 10.1001/archderm.110.6.862 pmid: 4613278
[22]	Schlüpen EM, Wollenberg A, Hänel S, et al. Detection of Herpes simplex virus in exacerbated Pemphigus vulgaris by polymerase chain reaction[J]. Dermatology, 1996, 192(4):312-316. pmid: 8864363
[23]	Tufano MA, Baroni A, Buommino E, et al. Detection of herpesvirus DNA in peripheral blood mononuclear cells and skin lesions of patients with pemphigus by polymerase chain reaction[J]. Br J Dermatol, 1999, 141(6):1033-1039. doi: 10.1046/j.1365-2133.1999.03201.x
[24]	Machado ARDSR, La Serra L, Turatti A, et al. Herpes simplex virus 1 and cytomegalovirus are associated with Pemphigus vulgaris but not with Pemphigus foliaceus disease[J]. Exp Dermatol, 2017, 26(10):966-968. doi: 10.1111/exd.2017.26.issue-10
[25]	Ruocco V, Wolf R, Ruocco E, et al. Viruses in pemphigus:A casual or causal relationship?[J]. Int J Dermatol, 1996, 35(11):782-784. pmid: 8915728
[26]	Gye J, Nam CH, Kim JS, et al. Pemphigus vulgaris in pregnancy associated with herpes virus type 1 infection[J]. Ann Dermatol, 2014, 26(2):258-260. doi: 10.5021/ad.2014.26.2.258
[27]	Pranteda G, Carlesimo M, Bottoni U, et al. Pemphigus vulgaris in a patient with arthritis and uveitis:Successful treatment with immunosuppressive therapy and acyclovir[J]. Dermatol Ther, 2014, 27(4):215-218. doi: 10.1111/dth.12120 pmid: 24548566
[28]	Esmaili N, Hallaji Z, Abedini R, et al. Pemphigus vulgaris and herpesviruses:Is there any relationship?[J]. Int J Dermatol, 2010, 49(11):1261-1265. doi: 10.1111/ijd.2010.49.issue-11
[29]	Mohammadi F, Khalili Z, Marashi SM, et al. The potential roles of herpesvirus and cytomegalovirus in the exacerbation of Pemphigus vulgaris[J]. Dermatol Pract Concept, 2018, 8(4):262-271. doi: 10.5826/dpc.0804a03 pmid: 30479853
[30]	Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis[J]. Nat Rev Dis Primers, 2018, 4:18017. doi: 10.1038/nrdp.2018.17 pmid: 29644994
[31]	Rodríguez Y, Vatti N, Ramírez-Santana C, et al. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease[J]. J Autoimmun, 2019, 102:8-37. doi: S0896-8411(19)30043-5 pmid: 31072742
[32]	Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis[J]. World J Gastroenterol, 2021, 27(1):19-36. doi: 10.3748/wjg.v27.i1.19
[33]	Berkun Y, Mimouni D, Shoenfeld Y. Pemphigus following hepatitis B vaccination:Coincidence or causality?[J]. Autoimmunity, 2005, 38(2):117-119. doi: 10.1080/08916930400027078
[34]	Ujiie I, Ujiie H, Yoshimoto N, et al. Prevalence of infectious diseases in patients with autoimmune blistering diseases[J]. J Dermatol, 2020, 47(4):378-384. doi: 10.1111/jde.v47.4
[35]	Agmon-Levin N, Ram M, Barzilai O, et al. Prevalence of hepatitis C serum antibody in autoimmune diseases[J]. J Autoimmun, 2009, 32(3/4):261-266. doi: 10.1016/j.jaut.2009.02.017
[36]	Sagi L, Baum S, Agmon-Levin N, et al. Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature[J]. Autoimmun Rev, 2011, 10(9):527-535. doi: 10.1016/j.autrev.2011.04.003 pmid: 21527361
[37]	Demirci GT, Aydingoz IE, Mansur AT, et al. Hepatitis C and hepatitis B virus infections in the etiopathogenesis of pemphigus[J]. An Bras Dermatol, 2014, 89(3):423-426. doi: S0365-05962014000300423 pmid: 24937815
[38]	Wang GQ, Xu HH, Wang YK, et al. Higher prevalence of human herpesvirus 8 DNA sequence and specific IgG antibodies in patients with pemphigus in China[J]. J Am Acad Dermatol, 2005, 52(3):460-467. doi: 10.1016/j.jaad.2004.10.882
[39]	Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19[J]. Nat Rev Microbiol, 2021, 19(3):141-154. doi: 10.1038/s41579-020-00459-7 pmid: 33024307
[40]	Solimani F, Mansour Y, Didona D, et al. Development of severe Pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2[J]. J Eur Acad Dermatol Venereol, 2021, 35(10):e649-e651. doi: 10.1111/jdv.17480 pmid: 34169588
[41]	Thongprasom K, Pengpis N, Phattarataratip E, et al. Oral pemphigus after COVID-19 vaccination[J]. Oral Dis, 2022, 28(Suppl 2):2597-2598. doi: 10.1111/odi.v28.S2
[42]	Koutlas IG, Camara R, Argyris PP, et al. Development of Pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine[J]. Oral Dis, 2022, 28(Suppl 2):2612-2613. doi: 10.1111/odi.v28.S2
[43]	Calabria E, Canfora F, Mascolo M, et al. Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination:A Case report of Pemphigus Vulgaris and a literature review[J]. Pathol Res Pract, 2022, 232:153834. doi: 10.1016/j.prp.2022.153834
[44]	Knechtl GV, SeyedJafari SM, Berger T, et al. Development of Pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient[J]. J Eur Acad Dermatol Venereol, 2022, 36(4):e251-e253.
[45]	Almasi-Nasrabadi M, Ayyalaraju RS, Sharma A, et al. New onset Pemphigus foliaceus following AstraZeneca COVID-19 vaccination[J]. J Eur Acad Dermatol Venereol, 2023, 37(1):e1-e3.
[46]	De Medeiros VLS, Monteiro-Neto AU, França DDT, et al. Pemphigus vulgaris after COVID-19:A case of induced autoimmunity[J]. SN Compr Clin Med, 2021, 3(8):1768-1772. doi: 10.1007/s42399-021-00971-8
[47]	Ruocco E, Ruocco V, Schiavo AL, et al. Viruses and pemphigus:An intriguing never-ending story[J]. Dermatology, 2014, 229(4):310-315. doi: 10.1159/000365845
[48]	Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases[J]. Crit Rev Microbiol, 2019, 45(4):394-412. doi: 10.1080/1040841X.2019.1614904 pmid: 31145640
[49]	Rojas M, Restrepo-Jiménez P, Monsalve DM, et al. Molecular mimicry and autoimmunity[J]. J Autoimmun, 2018, 95:100-123. doi: S0896-8411(18)30536-5 pmid: 30509385
[50]	Rose NR. Negative selection, epitope mimicry and autoimmunity[J]. Curr Opin Immunol, 2017, 49:51-55. doi: S0952-7915(17)30133-4 pmid: 29102863
[51]	Zhao ZS, Granucci F, Yeh L, et al. Molecular mimicry by Herpes simplex virus-type 1:Autoimmune disease after viral infection[J]. Science, 1998, 279(5355):1344-1347. pmid: 9478893
[52]	Jog NR, James JA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus[J]. Front Immunol, 2021, 11:623944. doi: 10.3389/fimmu.2020.623944
[53]	Li N, Aoki V, Liu Z, et al. From insect bites to a skin autoimmune disease:A conceivable pathway to endemic Pemphigus foliaceus[J]. Front Immunol, 2022, 13:907424. doi: 10.3389/fimmu.2022.907424
[54]	Ishii N. Significance of anti-desmocollin autoantibodies in pemphigus[J]. J Dermatol, 2023, 50(2):132-139. doi: 10.1111/jde.v50.2
[55]	Amber KT, Valdebran M, Grando SA. Non-desmoglein antibodies in patients with Pemphigus vulgaris[J]. Front Immunol, 2018, 9:1190. doi: 10.3389/fimmu.2018.01190 pmid: 29915578
[56]	Schwimmbeck PL, Dyrberg T, Drachman DB, et al. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with Herpes simplexvirus[J]. J Clin Invest, 1989, 84(4):1174-1180. doi: 10.1172/JCI114282 pmid: 2551924
[57]	Ahmed AR, Moy RL, Chia D, et al. Immune complexes in pemphigus and bullous pemphigoid[J]. Dermatologica, 1983, 166(4):175-180. pmid: 6343146
[58]	Aoyama Y, Nagai M, Kitajima Y. Binding of pemphigus vulgaris IgG to antigens in desmosome core domains excludes immune complexes rather than directly splitting desmosomes[J]. Br J Dermatol, 2010, 162(5):1049-1055. doi: 10.1111/j.1365-2133.2010.09672.x pmid: 20222919
[59]	Tomer Y, Villanueva R. Infection and autoimmune thyroid diseases[M]//Infection and Autoimmunity. Amsterdam:Elsevier, 2004:515-530.
[60]	Aibara N, Ohyama K. Revisiting immune complexes:Key to understanding immune-related diseases[J]. Adv Clin Chem, 2020, 96:1-17.
[61]	Cooksley H, Riva A, Katzarov K, et al. Differential expression of immune inhibitory checkpoint signatures on antiviral and inflammatory T cell populations in chronic hepatitis B[J]. J Interferon Cytokine Res, 2018, 38(7):273-282. doi: 10.1089/jir.2017.0109
[62]	Dong YJ, Li XF, Zhang L, et al. CD4⁺ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B[J]. BMC Immunol, 2019, 20(1):27. doi: 10.1186/s12865-019-0309-9
[63]	Jubel JM, Barbati ZR, Burger C, et al. The role of PD-1 in acute and chronic infection[J]. Front Immunol, 2020, 11:487. doi: 10.3389/fimmu.2020.00487 pmid: 32265932
[64]	Wang JY, Li C, Fu JJ, et al. Tim-3 regulates inflammatory cytokine expression and Th17 cell response induced by monocytes from patients with chronic hepatitis B[J]. Scand J Immunol, 2019, 89(5):e12755. doi: 10.1111/sji.2019.89.issue-5
[65]	Tavakolpour S, Mahmoudi H, Mirzazadeh A, et al. Pathogenic and protective roles of cytokines in pemphigus:A systematic review[J]. Cytokine, 2020, 129:155026. doi: 10.1016/j.cyto.2020.155026
[66]	Sugiyama H, Matsue H, Nagasaka A, et al. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with Pemphigus vulgaris[J]. Dermatology, 2007, 214(3):210-220. pmid: 17377382
[67]	Su W, Zhou Q, Ke Y, et al. Functional inhibition of regulatory CD4+CD25+T cells in peripheral blood of patients with Pemphigus vulgaris[J]. Clin Exp Dermatol, 2020, 45(8):1019-1026. doi: 10.1111/ced.v45.8
[68]	Veldman C, Höhne A, Dieckmann D, et al. Type I regulatory T cells specific for desmoglein 3 are more frequently detected in healthy individuals than in patients with Pemphigus vulgaris[J]. J Immunol, 2004, 172(10):6468-6475. doi: 10.4049/jimmunol.172.10.6468
[69]	Timoteo RP, da Silva MV, Miguel CB, et al. Th1/Th17-related cytokines and chemokines and their implications in the pathogenesis of Pemphigus vulgaris[J]. Mediators Inflamm, 2017, 2017:7151285.
[70]	Liu TM, Li S, Ying SN, et al. The IL-23/IL-17 pathway in inflammatory skin diseases:From bench to bedside[J]. Front Immunol, 2020, 11:594735. doi: 10.3389/fimmu.2020.594735
[71]	Grunwald MH, Katz I, Friedman-Birnbaum R. Association of pemphigus vulgaris and herpes simplex virus infection[J]. Int J Dermatol, 1986, 25(6):392-393. pmid: 3759316
[72]	Fernandes NC, Rampinelli H, Souza LM, et al. Refractory pemphigus foliaceus associated with herpesvirus infection:case report[J]. Rev Inst Med Trop Sao Paulo, 2017, 59:e41.
[73]	Chiu HY, Chang CY, Hsiao CH, et al. Concurrent cytomegalov-irus and herpes simplex virus infection in pemphigus vulgaris treated with rituximab and prednisolone[J]. Acta Derm Venereol, 2013, 93(2):200-201. doi: 10.2340/00015555-1429
[74]	Baum S, Atar I, Coster D, et al. Relationship between Pemphigus Vulgaris severity and PCR-positive Herpes simplex virus[J]. Acta Derm Venereol, 2022, 102:adv00703. doi: 10.2340/actadv.v102.917
[75]	Konda D, Chandrashekar L, Dhodapkar R, et al. Clinical markers of Herpes simplex virus infection in patients with pemphigus vulgaris[J]. J Am Acad Dermatol, 2023, 88(3):587-592. doi: 10.1016/j.jaad.2019.06.002
[76]	Brandão MLFB, Fernandes NC, Batista DP, et al. Refractory Pemphigus vulgaris associated with herpes infection:Case report and review[J]. Rev Inst Med Trop Sao Paulo, 2011, 53(2):113-117. doi: 10.1590/S0036-46652011000200010
[77]	Zhong ZY, Liao WT, Dai LY, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection[J]. Ann Rheum Dis, 2022, 81(4):584-591. doi: 10.1136/annrheumdis-2021-221650
[78]	Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies:Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6):1297-1309. doi: S0016-5085(17)30173-7 pmid: 28219691
[79]	Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with Pemphigus vulgaris and demonstrates a steroid-sparing effect[J]. Br J Dermatol, 2020, 182(5):1111-1119. doi: 10.1111/bjd.18482 pmid: 31487383
[80]	Frampton JE. Rituximab:A review in Pemphigus vulgaris[J]. Am J Clin Dermatol, 2020, 21(1):149-156. doi: 10.1007/s40257-019-00497-9 pmid: 31838645
[81]	Kusumoto S, Arcaini L, Hong XN, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. Blood, 2019, 133(2):137-146. doi: 10.1182/blood-2018-04-848044 pmid: 30341058
[82]	Smalls DJ, Kiger RE, Norris LB, et al. Hepatitis B virus reactivation:Risk factors and current management strategies[J]. Pharmacotherapy, 2019, 39(12):1190-1203. doi: 10.1002/phar.v39.12